Condition: Advanced Non-squamous Non-small-cell Lung Cancer · Metastatic Non-squamous Non Small Cell Lung Cancer · Sponsor: Allist Pharmaceuticals, Inc.
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Shanghai Allist Pharmaceuticals Co., Ltd · 021-80423288 · zhenhua.gong@allist.com.cn
Always discuss trial participation with your own doctor first.
| Anhui Province cancer hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Pecking Union Medical College Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Cancer Hospital Chinese Academy Of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tiantan Hospital, Captal Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Chest Hospital ,Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Fujian cancer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| The first Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center | Shenzhen, Guangdong, China | Not Yet Recruiting |
| Guangxi Medical University Cancer hospital & Guangxi Cancer Institute | Nanning, Guangxi, China | Not Yet Recruiting |
| Cangzhou hospital of integrated TCM-WM Hebei | Cangzhou, Hebei, China | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06416410